Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vudalimab · XmAb20717

Bispecific antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) · developed by Xencor

Phase 2 Most advanced trial
XNCR Developer
3 Registered trials

What is Vudalimab?

Vudalimab is an Fc-engineered bispecific antibody that binds both PD-1 and CTLA-4 on tumor-infiltrating T lymphocytes, blocking their inhibitory signaling to restore T-cell activation and proliferation. It is being studied in ovarian, endometrial, cervical and biliary tract cancers, clear cell carcinoma, and metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XmAb20717, Anti-PD-1/Anti-CTLA-4 XmAb20717
Drug type
Bispecific antibody
Targets
Programmed cell death protein 1 (PDCD1), Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4)
Mechanism
Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4)
Pathways
T-cell activation and proliferation
Therapy area
Oncology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
4I9I5X3Z6N

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05032040 Phase 2 Ovarian Cancer Active not recruiting XNCR
NCT05297903 Phase 2 Biliary Tract Cancer Completed XNCR
NCT05005728 Phase 2 Metastatic Castration-Resistant Prostate Cancer Completed XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cervical CarcinomaClear Cell CarcinomaEndometrial CancerMetastatic Castration-Resistant Prostate Cancer (mCRPC)Ovarian CancerBiliary Tract CancerMetastatic Castration-Resistant Prostate Cancer

Other drugs acting on PDCD1 / CTLA4

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind Vudalimab

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.